drugset / Trial / NCT00725686
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
NaSingle-groupOpen-labelTreatment
Summary
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
Timeline
- Start
- 2007-02
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 50 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 100 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 200 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 400 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 670 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 1000 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 1500 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 2250 ug | Intravitreal |
| Subject | PF-04523655 | Small interfering RNA (siRNA) | 3000 ug | Intravitreal |